 |
2 Products |  |
0 Diseases | | 2 Products |
|
0 Trials |  |
27 News |  |
- || KA2237 / Karus Therap
P1 data, Preclinical, Journal: Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. (Pubmed Central) - Apr 15, 2022
P1
Thirty-three percent discontinued treatment due to adverse events. KA2237 induced objective responses in indolent and aggressive lymphoma (overall response rate 37%; complete response n = 4, partial response n = 3).
- || KA2507 / Karus Therap, UT MD Anderson Cancer Center
P1 data, Preclinical, Journal, Epigenetic controller: Preclinical development and first in human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors. (Pubmed Central) - Apr 8, 2022
P1
In a phase I study, KA2507 showed selective target engagement, no significant toxicities, and prolonged disease stabilization in a subset of patients. Further clinical studies of KA2507 are warranted, as a single agent or, preferably, combined with other immune-oncology drugs.
- ||||| KA2237 / Karus Therap
Clinical: Our study done in collaboration with Karus Therapeutics and led by Dr. Nastoupil found KA2237 (dual p110β/p110δ inhibitor) to be an effective therapeutic option for patients with refractory B-cell lymphoma without an acceptable standard of care option. https://t.co/8hnz5bgSFC (Twitter) - Aug 10, 2021
- | KA2237 / Karus Therap
Journal: Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. (Pubmed Central) - May 15, 2021
In addition, combining KA2237 with currently available chemotherapeutic agents synergistically inhibited metabolic growth. This study elucidates the compensatory upregulated PI3K/AKT axis that emerges in ibrutinib-resistant cells.
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
Enrollment change, Trial withdrawal, Metastases: A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer (clinicaltrials.gov) - Feb 3, 2021
P2, N=0, Withdrawn, Sponsor: Karus Therapeutics Limited
This study elucidates the compensatory upregulated PI3K/AKT axis that emerges in ibrutinib-resistant cells. N=40 --> 0 | Active, not recruiting --> Withdrawn
- KA2507 / Karus Therap, UT MD Anderson Cancer Center
[VIRTUAL] Characterising the role of HDAC6 in the control of human macrophage IL-10 production (e-Poster Display) - Oct 29, 2020 - Abstract #ESMOIO2020ESMO_IO_210;
Conclusions These data highlight an emerging role for HDAC6 in modulating the activity of the innate immune system and lend supporting rationale for further study of HDAC6 inhibitors in combination with immunotherapy agents. Data relating to IL-10 expression from the recent clinical study of KA2507 are currently pending.
- || KA2507 / Karus Therap, UT MD Anderson Cancer Center
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Aug 8, 2020
P1, N=20, Completed, Sponsor: Karus Therapeutics Limited
Data relating to IL-10 expression from the recent clinical study of KA2507 are currently pending. Recruiting --> Completed | N=36 --> 20 | Trial completion date: Jan 2021 --> May 2020 | Trial primary completion date: Jan 2021 --> May 2020
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
Enrollment closed, Phase classification, Metastases: A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer (clinicaltrials.gov) - May 22, 2020
P2, N=40, Active, not recruiting, Sponsor: Karus Therapeutics Limited
Recruiting --> Completed | N=36 --> 20 | Trial completion date: Jan 2021 --> May 2020 | Trial primary completion date: Jan 2021 --> May 2020 Not yet recruiting --> Active, not recruiting | Phase classification: P1/2 --> P2
- KA2507 / Karus, UT MD Anderson Cancer Center
[VIRTUAL] Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_151;
P1
The median age was 56 years (27-78 years) and 13 were males. The most common tumor types were adenoid cystic carcinoma (ACC, n=6) and colorectal cancer (n=4).
- fluorouracil / Generic mfg.
[VIRTUAL] A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11). (Poster Board 260) - Feb 27, 2020 - Abstract #ASCO2020ASCO_538;
P2
In second line therapy oxaliplatin and 5FU and ivosedinib for IDH1 mutated cancers are options [Lamarca, 2019; Abou-Alfa, 2019] however there remains significant unmet need for patients without actionable alterations...The study received regulatory and ethical approval to proceed in January 2020 and enrolment is in progress. Research Funding: Karus Therapeutics Ltd
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Feb 23, 2020
P1, N=36, Recruiting, Sponsor: Karus Therapeutics Limited
Research Funding: Karus Therapeutics Ltd Trial completion date: Oct 2019 --> Jan 2021 | Trial primary completion date: Oct 2019 --> Jan 2021
- || KA2507 / Karus Therap, UT MD Anderson Cancer Center
New P1/2 trial, Metastases: A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer (clinicaltrials.gov) - Dec 3, 2019
P1/2, N=48, Not yet recruiting, Sponsor: Karus Therapeutics Limited
- KA2237 / Karus, Rituxan (rituximab) / Roche, Biogen
Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5835;
P1
The recommended phase II dose is 200mg daily . The findings of this study support the further evaluation of KA2237.
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Jul 18, 2019
P1, N=36, Recruiting, Sponsor: Karus Therapeutics Limited
The findings of this study support the further evaluation of KA2237. Trial completion date: Jun 2019 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Oct 2019
- || CVL237 / Convalife
Trial completion, Enrollment change, Trial completion date: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Feb 6, 2019
P1, N=23, Completed, Sponsor: Karus Therapeutics Limited
Trial completion date: Jun 2019 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Oct 2019 Recruiting --> Completed | N=53 --> 23 | Trial completion date: May 2019 --> Dec 2018
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Feb 5, 2019
P1, N=30, Recruiting, Sponsor: Karus Therapeutics Limited
Recruiting --> Completed | N=53 --> 23 | Trial completion date: May 2019 --> Dec 2018 Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Oct 2018 --> Jun 2019
- | CVL237 / Convalife
Trial primary completion date: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Aug 27, 2018
P1, N=53, Recruiting, Sponsor: Karus Therapeutics Limited
Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Oct 2018 --> Jun 2019 Trial primary completion date: May 2018 --> Oct 2018
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
Trial primary completion date: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Aug 27, 2018
P1, N=30, Recruiting, Sponsor: Karus Therapeutics Limited
Trial primary completion date: May 2018 --> Oct 2018 Trial primary completion date: Mar 2018 --> Oct 2018
- KA2507 / Karus Therap, UT MD Anderson Cancer Center
Enrollment open, Trial initiation date: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Aug 21, 2017
P1, N=30, Recruiting, Sponsor: Karus Therapeutics Limited
Trial primary completion date: Mar 2018 --> Oct 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Aug 2017
- | KA2507 / Karus Therap, UT MD Anderson Cancer Center
New P1 trial: Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (clinicaltrials.gov) - Jan 3, 2017
P1, N=30, Not yet recruiting, Sponsor: Karus Therapeutics Limited
- || CVL237 / Convalife
Enrollment change: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Dec 23, 2016
P1, N=53, Recruiting, Sponsor: Karus Therapeutics Limited
Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Aug 2017 N=38 --> 53
- CVL237 / Convalife
Enrollment open: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Aug 11, 2016
P1, N=38, Recruiting, Sponsor: Karus Therapeutics Limited
N=38 --> 53 Not yet recruiting --> Recruiting
- CVL237 / Convalife
New P1 trial: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Feb 10, 2016
P1, N=38, Not yet recruiting, Sponsor: Karus Therapeutics Limited